Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives

Advanced Molecular Solutions for Cancer Therapy—The Good, the Bad, and the Ugly of the Biomarker Paradigm

“…In contrast, the economic incentives of the precision medicine that tries to tailor the treatment to the patient’s characteristics are still limited, especially for low-income countries [ 13 , 14 ]. Owing to these (mostly desired rather than real) benefits, BMP serves to standardize the oncological recommendations and procedures (e.g., [ 15 , 16 ]).…”